NeuroSense amends JonesTrading equity distribution agreement for up to $3.79 million share sales
NRSN•SEC effectiveness date
The SEC declared the new Form F-3 effective on July 31, 2026.
Shares already sold under the program
6,762,825 ordinary shares have been sold under the program for net proceeds of about $6.7 million.
Updated prospectus permits up to $3.79 million in sales
The updated prospectus supplement permits sales of ordinary shares with an aggregate offering price up to $3.79 million.
Amended sales agreement tied to new registration statement
NeuroSense amended its JonesTrading Capital on Demand sales agreement to align it with a new Form F-3 registration statement.
